CAJ | 학술논문

目的：探讨沉默信息调节因子2相关酶1(SIRT1)在骨性关节炎(OA)正常滑膜组织及细胞中表达的差异性。方法膝关节滑膜细胞培养传代,甲苯胺蓝染色观察细胞形态,Western blot 法检测滑膜组织及细胞中 SIRT1的表达情况；免疫组织化学法对滑膜细胞检测 SIRT1表达情况及表达部位。结果甲苯胺蓝实验显示 OA 及正常滑膜细胞无明显形态学差异；免疫细胞化学法显示 SIRT1在滑膜细胞胞质中广泛表达,染色强度 OA 组较正常组明显降低(t =20．208, P <0．01)；Western blot 法显示在滑膜细胞中 OA 组 SIRT1表达明显低于正常对照组((t =8．619,P <0．01)；在滑膜组织中 OA 组 SIRT1的表达亦明显低于正常对照组(t =7．664,P<0．01)。结论 SIRT1与 OA 导致滑膜炎的发生发展密切相关,为 SIRT1可以作为 OA 治疗的靶点提供一个新的理论依据。
목적：탐토침묵신식조절인자2상관매1(SIRT1)재골성관절염(OA)정상활막조직급세포중표체적차이성。방법슬관절활막세포배양전대,갑분알람염색관찰세포형태,Western blot 법검측활막조직급세포중 SIRT1적표체정황；면역조직화학법대활막세포검측 SIRT1표체정황급표체부위。결과갑분알람실험현시 OA 급정상활막세포무명현형태학차이；면역세포화학법현시 SIRT1재활막세포포질중엄범표체,염색강도 OA 조교정상조명현강저(t =20．208, P <0．01)；Western blot 법현시재활막세포중 OA 조 SIRT1표체명현저우정상대조조((t =8．619,P <0．01)；재활막조직중 OA 조 SIRT1적표체역명현저우정상대조조(t =7．664,P<0．01)。결론 SIRT1여 OA 도치활막염적발생발전밀절상관,위 SIRT1가이작위 OA 치료적파점제공일개신적이론의거。
Objective To investigate the expression of silent information regulator factor 2 related enzyme 1 (SIRT1) in osteoarthritis ( OA) synovial membrane tissue and cells. Methods Knee joint synovial membrane cells were cultured, and the synovial membrane cells morphology was detected by toluidine blue staining. The ex-pression of SIRT1 protein in osteoarthritis synovial membrane tissue and cells was detected by Western blot. The expression and distribution of SIRT1 protein was also detected by immunohistochemistry. Results Toluidine blue assay showed that OA and normal synovial cells had no obvious morphological difference; Immunohistochemistry showed that SIRT1 was widely expressed in synovial cells, the staining intensity of OA group was significantly de-creased compared with normal group (t = 20. 208, P < 0. 01); Western blot showed that the expression of SIRT1 in synovial cells in OA group was significantly lower than that in normal control group (t = 8. 619, P < 0. 01); The expression of SIRT1 in synovium of OA group was obviously lower than that in the normal group (t = 7. 664, P <0. 01). Conclusion The low expression of SIRT1 may play an essential role in OA progression, and the research provides a new theoretical basis for SIRT1 as therapeutic target in OA treatment.